Recently launched
Cyclophosphamide Injection
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur eleifend est quis mauris vehicula, eleifend mollis libero rutrum.
How can we help you?
Monitoring & Managing Adverse Reactions
Information about immune-mediated and other adverse reactions in patients receiving Cyclophosphamide.
Patient Access & Reimbursement Support
Let us help answer questions about billing and coding for Cyclophosphamide.
Dosing & Administration
Information on preparation, storage, administration, and dosing modifications for Cyclophosphamide.
Ask AuroMedics
We are committed to helping you get your product questions answered. Connect with us now.
Ordering Cyclophosphamide Injection
Important Safety Information
Indications
1.1 Malignant Diseases
Cyclophosphamide Injection is indicated for the treatment of:
- malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma
- multiple myeloma
- leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration)
- mycosis fungoides (advanced disease)
- neuroblastoma (disseminated disease)
- adenocarcinoma of the ovary
- retinoblastoma
- carcinoma of the breast